Wipro and Cisco collaborate to deliver SD-WAN Transformation services to Olympus
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it will deliver managed Software-Defined Wide Area Network (SD-WAN) transformation services to Olympus leveraging Cisco technology.
Headquartered in Tokyo, Japan, Olympus is passionate about the solutions it creates for the medical, life sciences, and industrial equipment industries, as well as cameras and audio products. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping detect, prevent, and treat disease, furthering scientific research, ensuring public safety, and capturing images of the world.
As a part of this engagement, Wipro will use its proprietary managed network services solution, #WANFreedom to re-architect Olympus’s WANs and enable support across distributed applications in a hybrid multi-cloud environment. The new network infrastructure will drastically improve Olympus’s application performance to deliver superior end user experience, resulting in increased business productivity, agility and reduced costs for IT.
The managed services model allows Wipro to deliver optimal cost-effectiveness and reliability to its customers by monitoring, maintaining, and managing services continuously. Wipro's managed SD-WAN #WANFreedom services are enabled by Cisco's global Secure SD-WAN Managed Services Partner (MSP) Program.
Stephen Kneebone, Global CIO, Olympus,said,“As we move into a world where businesses are focused on being more resilient by accelerating digital transformation, we believe that we are keeping pace with the change. Our cloud adoption and application migration initiatives demand high performance from the network. With Wipro, we have embarked on our WAN transformation journey that improves application experience and reduces our OPEX as Wipro’s #WANFreedom solution standardizes our global WAN spread across 40+ countries. Wipro’s centralized platform for contract management will consolidate our service providers and is expected to provide up to a 30 percent cost reduction.”
Kiran Desai, Senior Vice President, Cloud and Infrastructure Services, Wipro Limited, said, “We are excited to be selected by Olympus as their SD-WAN transformation partner. Wipro’s #WANFreedom provides comprehensive lifecycle services spanning consulting, planning and design, implementation, and managed network services. Our as-a-service model powered by integrated automation platform will create a cognitive digital networking infrastructure for Olympus, which is secure and dynamic. Its enhanced capabilities will help Olympus gain flexibility to access multi-cloud services, reduce overhead, and support new applications in its digital transformation journey.”
Scott Harrell, Senior Vice President and General Manager of Cisco's Intent-Based Networking Group,said, "As organizations adopt the cloud for key applications, their WAN architecture must also evolve to provide the best experience for their users and improved efficiency for their organizations. Agility and security are paramount in this transition. Through Cisco's secure SD-WAN technology and Cisco's new Service Creation Program for partners, Wipro can help customers like Olympus secure their connectivity to multiple clouds, optimize their application experiences and accelerate their digital transformation journeys."
About Wipro Limited
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) is a leading global information technology, consulting and business process services company. We harness the power of cognitive computing, hyper-automation, robotics, cloud, analytics, and emerging technologies to help our clients adapt to the digital world and make them successful. A company recognized globally for its comprehensive portfolio of services, strong commitment to sustainability, and good corporate citizenship, we have over 180,000 dedicated employees serving clients across six continents. Together, we discover ideas and connect the dots to build a better and a bold new future. For more information, please visit www.wipro.com.
Forward-looking and Cautionary Statements
The forward-looking statements contained herein represent Wipro’s beliefs regarding future events, many of which are by their nature, inherently uncertain and outside Wipro’s control. Such statements include, but are not limited to, statements regarding Wipro’s growth prospects, its future financial operating results, and its plans, expectations and intentions. Wipro cautions readers that the forward-looking statements contained herein are subject to risks and uncertainties that could cause actual results to differ materially from the results anticipated by such statements. Such risks and uncertainties include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, complete proposed corporate actions, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our business and industry. The conditions caused by the COVID-19 pandemic could decrease technology spending, adversely affect demand for our products, affect the rate of customer spending and could adversely affect our customers’ ability or willingness to purchase our offerings, delay prospective customers’ purchasing decisions, adversely impact our ability to provide on-site consulting services and our inability to deliver our customers or delay the provisioning of our offerings, all of which could adversely affect our future sales, operating results and overall financial performance. Our operations may also be negatively affected by a range of external factors related to the COVID-19 pandemic that are not within our control. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission, including, but not limited to, Annual Reports on Form 20-F. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tanner Pharma Group Expands Ex-US Access Program to Provide LEUKINE® for Use in Patients with Respiratory Illness Associated with COVID-198.3.2021 16:53:00 CET | Press release
Tanner Pharma Group (Tanner) today announced expansion of the LEUKINE Access Program (LeAP) as a channel for distribution of LEUKINE® (sargramostim) in international markets. LEUKINE®, approved by the US FDA in 1991 and now manufactured by Partner Therapeutics (PTx), is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that stimulates the immune system and has been used in leukemia patients to reduce the risk of infection. PTx recently announced that a clinical trial of Leukine® conducted in Belgium of hospitalized COVID-19 patients suffering from acute hypoxic respiratory failure requiring supplemental oxygen met the primary endpoint of significant improvement in lung function. Improvement in oxygenation of at least 33% or more from baseline was seen in 54% of patients on the LEUKINE® plus standard-of-care (SOC) arm versus 26% of patients on SOC (p=.0147). Tanner provides a regulatory-compliant pathway to make LEUKINE® available in international markets. If a pat
H.I.G. Capital Expands European WhiteHorse Team with the Addition of Laurent Vaille and Charles Bourgeois8.3.2021 16:30:00 CET | Press release
H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with over €35 billion of equity capital under management, is pleased to announce the expansion of its European WhiteHorse team with the addition of Laurent Vaille and Charles Bourgeois as Principals. Laurent will be based in H.I.G.’s London office, and Charles is based in H.I.G.’s Paris office. Laurent has 13 years of experience in direct lending and corporate finance. He was previously an Executive Director in the Private Debt division of Tikehau Capital in Paris. Prior to that, he worked for Ernst & Young and Deloitte Finance. Charles has 13 years of experience in direct lending and corporate finance. Prior to joining H.I.G., he was an Executive Director in the Private Debt division of Tikehau Capital in Paris. He was previously with GE Capital in the leveraged finance division, after working at SG and LD&A Jupiter. Commenting on the hire, Pascal Meysson, Head of H.I.G. WhiteHorse Europe, said, “Hiring profe
PerkinElmer Adds HPLC Columns to Consumables Portfolio8.3.2021 16:22:00 CET | Press release
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it has added state-of-the-art columns and chemistries to its LC consumables portfolio by acquiring ES Industries, based in West Berlin, New Jersey in the U.S. ES Industries is known for its innovative and highly efficient HPLC and supercritical fluid chromatography (SFC) column chemistries. The team has over 40 years of experience delivering columns with superior reliability, scalability, and reproducibility that are used routinely for method development processes, LC/MS analysis, quality control and preparative purification. Building on PerkinElmer’s https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.perkinelmer.com%2Fcategory%2Fliquid-chromatography-hplc-uhplc-instruments&esheet=52392346&newsitemid=20210308005611&lan=en-US&anchor=recently+announced+LC+300TM+HPLC%2FUHPLC+and+SimplicityChromTM+CDS+solution&index=3&md5=8aaa6199b7c1a347615a2b8ae0dd87b1 recently announ
Veristat Congratulates Origin Biosciences for FDA Approval of Nulibry During the Week of Rare Disease Day 20218.3.2021 15:25:00 CET | Press release
Veristat, a scientific-minded, global clinical research organization (CRO), today congratulated Origin Biosciences for their FDA approval of Nulibry (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A. This rare disease product received FDA approval on Friday, 26 February 2021, during the week when the world celebrated #RareDiseaseDay2021. Veristat’s biostatisticians, programmers, and medical writers collaborated with Origin Biosciences to support the New Drug Application (NDA) for Nulibry. The entire Veristat team is honored to know that the hard work and perseverance of the combined Origin/Veristat team brought new hope for children whose lives are shortened by the devastating disease MoCD Type A. “We thank the entire Veristat team who worked diligently to help us bring this critical therapy to patients with no other FDA-approved treatment options,” said Dr. Liza Squires, Origin Chief Medical
CBS News “Global Thought Leaders” Series Features Echosens: Video Showcases FibroScan ® as Medical Gold Standard8.3.2021 15:01:00 CET | Press release
Echosens, a high-technology company offering the FibroScan® family of products, is pleased to announce that it has been chosen for the “Global Thought Leaders” series broadcast on CBS News. View a short video highlighting the Company’s groundbreaking work in the development of vital medical resources, including FibroScan®, a noninvasive solution for measuring liver elasticity and fat content of the liver at the point of care. “We’re pleased to be selected by CBS News and proud of the video created at our international headquarters in Paris which captures the essence of Echosens, including interviews with some of our top leaders and a clinician performing a FibroScan® exam with her patient,” says Dominique Legros, Group CEO, Echosens. “Reliable, accurate and affordable, FibroScan® is designed to address a growing liver disease epidemic. Nonalcoholic fatty liver disease (NAFLD) affects approximately 25% of the worldwide population and as many as 6% are affected by NASH, which is expected
Infor and C3 AI Form Strategic Partnership to Deliver Scalable Enterprise AI Industry Applications8.3.2021 15:00:00 CET | Press release
C3 AI (NYSE: AI), a leading enterprise AI software provider, and Infor, an ERP technology cloud leader, today announced a wide-ranging strategic alliance designed to jointly expand enterprise-class artificial intelligence (AI) solutions across applicable industries to extend Infor’s native machine learning capabilities. This will allow Infor to explore expansion of its industry offerings into edge scenarios and analyze ways to provide deeper capabilities beyond standard Infor offerings. Infor plans to market, license, and deploy C3 AI prebuilt solutions to Infor customers under the Infor brand and to explore new solutions using the C3 AI® Suite. Infor and C3 AI expect to leverage both companies’ existing digital portfolios to collaborate on new integrated enterprise AI applications that can support specific industry needs. The initial focus will be on predictive maintenance surrounding Internet of Things (IoT) systems with the goal of providing a more proactive and accurate maintenance
NielsenIQ Establishes Independence as a Standalone Company8.3.2021 15:00:00 CET | Press release
Today, NielsenIQ begins its next chapter as an independent company with the closing of its acquisition by Advent International in partnership with incoming Executive Chairman and CEO James “Jim” Peck. As a standalone business, NielsenIQ is better positioned to accelerate its transformation and strengthen its market-leading position. To move forward as a definitive leader in the FMCG industry and usher in a new era of technological advancements and innovation, three new leaders will join NielsenIQ. Mohit Kapoor joins as Chief Technology Officer, overseeing all aspects of technology. Steve Matthesen, a Nielsen veteran, joins as Chief Strategy Officer to help develop and execute the corporate strategy and other key initiatives. Curt Miller joins as Chief Transformation Officer to drive organizational alignment that supports NielsenIQ’s growth strategy. “NielsenIQ has a unique opportunity to become a nimble partner with the flexibility to increase strategic investments and innovation in th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom